Market research
EVGN Evogene
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 9M
- P/E ratio
- Not available
- Analyst target
- 2.15
- Dividend yield
- Not available
- Beta
- 0.68
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- IL0011050551
- Market cap
- 9M
- P/E ratio
- Not available
- Analyst target
- 2.15
- Dividend yield
- Not available
- Beta
- 0.68
About
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD); and with ELEO, Inc. to develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the EVGN discussion.
5 years, 4 months ago
Evogene Ltd is currently in a long term downtrend where the price is trading 31.2% below its 200 day moving average.
From a valuation standpoint, the stock is 89.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 135.9.
Evogene Ltd's total revenue rose by 202.6% to $351K since the same quarter in the previous year.
Its net income has dropped by 33.6% to $-8M since the same quarter in the previous year.
Finally, its free cash flow fell by 33.1% to $-7M since the same quarter in the previous year.
Based on the above factors, Evogene Ltd gets an overall score of 2/5.